2024
Obesity, Growth, Development, Metabolic Disorder, and Insulin Resistance in Pediatrics
Santoro N, Galderisi A, Caprio S. Obesity, Growth, Development, Metabolic Disorder, and Insulin Resistance in Pediatrics. 2024, vol1:608-vol1:616. DOI: 10.1201/9781003437734-70.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseType 2 diabetesInsulin resistanceAdolescent obesityAssociated with precocious pubertyDevelopment of prediabetesCardiometabolic risk factorsPathogenesis of insulin resistanceFatty liver diseasePrecocious pubertyClinical peculiaritiesPediatric obesityLiver diseaseRisk factorsGlobal health challengeMetabolic disordersObesityFatty liverPathological complicationsPotential mechanismsInsulinHealth challengesChildrenComplicationsDyslipidemia
2023
Obesity, Growth, Development, Metabolic Disorder, and Insulin Resistance in Pediatrics
Santoro N, Galderisi A, Caprio S. Obesity, Growth, Development, Metabolic Disorder, and Insulin Resistance in Pediatrics. 2023, 608-616. DOI: 10.1201/9781003437673-70.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseType 2 diabetesInsulin resistanceAdolescent obesityCardiometabolic risk factorsMajor global health challengeFatty liver diseaseDevelopment of prediabetesGlobal health challengeClinical peculiaritiesFatty liverLiver diseasePediatric obesityRisk factorsPrecocious pubertyMetabolic disordersPathological complicationsObesityHealth challengesPsychosocial conditionsPotential mechanismsDiabetesEarly ageChildrenDyslipidemiaComparison of Metabolic Response to Colonic Fermentation in Lean Youth vs Youth With Obesity
Galuppo B, Umano G, Li Z, Van Name M, Samuels S, Kien C, Cline G, Wagner D, Barbieri E, Tricò D, Santoro N. Comparison of Metabolic Response to Colonic Fermentation in Lean Youth vs Youth With Obesity. JAMA Network Open 2023, 6: e2312530. PMID: 37159195, PMCID: PMC10170343, DOI: 10.1001/jamanetworkopen.2023.12530.Peer-Reviewed Original ResearchConceptsInsulin sensitivity indexCross-sectional studyFree fatty acidsColonic fermentationActive glucagon-like peptide-1Plasma free fatty acidsGlucagon-like peptide-1Indigestible dietary carbohydratesReduction of ghrelinActive GLP-1Health care burdenBody mass indexMetabolic responseInsulin-resistant groupLean youthObese insulinOIS groupPYY responseAnorexigenic responsePediatric obesityMass indexTyrosine tyrosineInsulin resistanceIntravenous infusionHormone secretionClinical features and metabolic complications for non-alcoholic fatty liver disease (NAFLD) in youth with obesity
Barbieri E, Santoro N, Umano G. Clinical features and metabolic complications for non-alcoholic fatty liver disease (NAFLD) in youth with obesity. Frontiers In Endocrinology 2023, 14: 1062341. PMID: 36733529, PMCID: PMC9887046, DOI: 10.3389/fendo.2023.1062341.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseInsulin resistancePediatric obesityDevelopment of NAFLDWhole-body insulin resistanceFatty liver diseaseType 2 diabetesAdipose tissue lipolysisCommon metabolic diseaseMetabolic complicationsClinical featuresLiver diseasePediatric populationTherapeutic optionsEctopic tissuePathophysiologic underpinningsTissue lipolysisRole of geneticsMetabolic diseasesObesityControl of insulinGrowth hormoneClinical implicationsDiseaseFatty acids
2019
Chapter 11 Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Pathophysiologic Links and Potential Implications
Galderisi A, Martino M, Santoro N. Chapter 11 Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Pathophysiologic Links and Potential Implications. 2019, 91-99. DOI: 10.1016/b978-0-323-55138-0.00011-5.BooksNonalcoholic fatty liver diseaseFatty liver diseaseType 2 diabetesLiver diseasePediatric nonalcoholic fatty liver diseasePathophysiology of NAFLDEnd-stage liver diseaseIndependent risk factorPathophysiologic linkCommon complicationSimple steatosisPediatric obesityInsulin resistanceRisk factorsType 2Disease severityDiseaseDiabetesWide spectrumComplicationsPotential implicationsSteatosisObesityPathophysiologySeverity